Form 4: BioMarin EVP Gregory Friberg Reports Stock and Option Awards

Gregory Friberg, EVP and Chief R&D Officer at BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units and stock options.

Summary

• Gregory R Friberg, EVP, Chief R&D Officer of BioMarin Pharmaceutical Inc., reported changes in beneficial ownership on September 30, 2024.
• Friberg acquired 21,190 shares of common stock and 7,870 shares of common stock through restricted stock units.
• Friberg was also granted options to purchase 49,850 shares of common stock at an exercise price of $70.29.
• The options vest in installments beginning September 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grants themselves are a positive sign of incentivization, but the filing itself is simply a procedural update.

Positives

• The grant of restricted stock units and stock options to a key executive aligns their interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option and restricted stock unit grants are common practices in the pharmaceutical industry to incentivize and retain key executives, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedule of the options (12/48th on the first anniversary, then monthly) is a typical vesting arrangement.

Stakeholder Impact

• The stock option and restricted stock unit grants incentivize the executive to work towards increasing shareholder value.

Key Dates